MedTrace Logo

Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

NCT03406585 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-03

No results posted yet for this study

Summary

To investigate the safety and tolerance after allogeneic infusion of WJMSCs intravenously in adult patients diagnosed with type 1 diabetes.

Conditions

  • Type1 Diabetes Mellitus

Interventions

DRUG

ProTrans: Allogeneic transplantation with WJMSCs

The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.

DRUG

Placebos

Placebo treatment

Sponsors & Collaborators

  • NextCell Pharma Ab

    lead INDUSTRY

Principal Investigators

  • Per-Ola Carlsson, MD, PhD · NextCell Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2020-07-01
Completion
2020-09-04

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406585 on ClinicalTrials.gov